Literature DB >> 11292821

Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase.

B J Michell1, T Tiganis, D Stapleton, F Katsis, D A Power, A T Sim, B E Kemp.   

Abstract

Endothelial nitric-oxide synthase (eNOS) is an important regulatory enzyme in the cardiovascular system catalyzing the production of NO from arginine. Multiple protein kinases including Akt/PKB, cAMP-dependent protein kinase (PKA), and the AMP-activated protein kinase (AMPK) activate eNOS by phosphorylating Ser-1177 in response to various stimuli. During VEGF signaling in endothelial cells, there is a transient increase in Ser-1177 phosphorylation coupled with a decrease in Thr-495 phosphorylation that reverses over 10 min. PKC signaling in endothelial cells inhibits eNOS activity by phosphorylating Thr-495 and dephosphorylating Ser-1177 whereas PKA signaling acts in reverse by increasing phosphorylation of Ser-1177 and dephosphorylation of Thr-495 to activate eNOS. Both phosphatases PP1 and PP2A are associated with eNOS. PP1 is responsible for dephosphorylation of Thr-495 based on its specificity for this site in both eNOS and the corresponding synthetic phosphopeptide whereas PP2A is responsible for dephosphorylation of Ser-1177. Treatment of endothelial cells with calyculin selectively blocks PKA-mediated dephosphorylation of Thr-495 whereas okadaic acid selectively blocks PKC-mediated dephosphorylation of Ser-1177. These results show that regulation of eNOS activity involves coordinated signaling through Ser-1177 and Thr-495 by multiple protein kinases and phosphatases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292821     DOI: 10.1074/jbc.C100122200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  155 in total

1.  Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism.

Authors:  Mingxia Gu; Nicholas M Mordwinkin; Nigel G Kooreman; Jaecheol Lee; Haodi Wu; Shijun Hu; Jared M Churko; Sebastian Diecke; Paul W Burridge; Chunjiang He; Frances E Barron; Sang-Ging Ong; Joseph D Gold; Joseph C Wu
Journal:  Eur Heart J       Date:  2014-11-02       Impact factor: 29.983

2.  N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase.

Authors:  Hsin-Han Hou; Bruce D Hammock; Kou-Hui Su; Christophe Morisseau; Yu Ru Kou; Susumu Imaoka; Ami Oguro; Song-Kun Shyue; Jin-Feng Zhao; Tzong-Shyuan Lee
Journal:  Cardiovasc Res       Date:  2011-11-08       Impact factor: 10.787

Review 3.  Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders.

Authors:  Pitchai Balakumar; Sonam Kathuria
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

4.  Expression of endothelial nitric oxide synthase protein is not necessary for mechanical strain-induced nitric oxide production by cultured osteoblasts.

Authors:  V Das-Gupta; R A Williamson; A A Pitsillides
Journal:  Osteoporos Int       Date:  2012-03-09       Impact factor: 4.507

5.  Protein kinase A-alpha directly phosphorylates FoxO1 in vascular endothelial cells to regulate expression of vascular cellular adhesion molecule-1 mRNA.

Authors:  Ji-Won Lee; Hui Chen; Philomena Pullikotil; Michael J Quon
Journal:  J Biol Chem       Date:  2010-12-22       Impact factor: 5.157

6.  New Insights into the Molecular Basis of the Antiphospholipid Syndrome.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Drug Discov Today Dis Mech       Date:  2011

7.  Rate, affinity and calcium dependence of nitric oxide synthase isoform binding to the primary physiological regulator calmodulin.

Authors:  Jonathan L McMurry; Carol A Chrestensen; Israel M Scott; Elijah W Lee; Aaron M Rahn; Allan M Johansen; Brian J Forsberg; Kyle D Harris; John C Salerno
Journal:  FEBS J       Date:  2011-11-11       Impact factor: 5.542

8.  Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect.

Authors:  Leslie G Cook; Valorie L Chiasson; Cheng Long; Gang-Yi Wu; Brett M Mitchell
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

Review 9.  Endothelial nitric oxide synthase and endothelial dysfunction.

Authors:  Paul L Huang
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

10.  Vascular Endothelial Growth Factor Increases Endothelial Nitric Oxide Synthase Transcription In Huvec Cells.

Authors:  Esther Koai; Tibisay Rincon Rios; John Edwards
Journal:  Webmedcentral       Date:  2010-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.